Aditxt, Inc. Operating Expenses
Aditxt, Inc. (ADTX) reported Operating Expenses of $4.36 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-05-20
- Aditxt, Inc. operating expenses for the quarter ending 2026-03-31 was $4.36M, a 22.18% decline year-over-year.
- Aditxt, Inc. operating expenses for the quarter ending 2025-12-31 was $4.67M, a 16.36% decline year-over-year.
- Aditxt, Inc. operating expenses for the quarter ending 2025-09-30 was $3.14M, a 25.93% decline year-over-year.
- Aditxt, Inc. operating expenses for the quarter ending 2025-06-30 was $6.15M, a 2.59% increase year-over-year.
- Aditxt, Inc. operating expenses for fiscal 2025 was $19.57M, a 28.50% decline from fiscal 2024.
- Aditxt, Inc. operating expenses for fiscal 2024 was $27.37M, a 5.47% increase from fiscal 2023.
- Aditxt, Inc. operating expenses for fiscal 2023 was $25.95M, a 1.18% increase from fiscal 2022.
- Aditxt, Inc. operating expenses for fiscal 2022 was $25.65M, a 38.88% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-03-31 | $4.36M 10-Q · filed 2026-05-20 | $9.03M derived: sum of 2 quarters · filed 2026-05-20 | $12.17M derived: sum of 3 quarters · filed 2026-05-20 | $18.33M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $7.81M derived: sum of 2 quarters · filed 2026-03-31 | $13.96M derived: sum of 3 quarters · filed 2026-03-31 | $19.57M 10-K · filed 2026-03-31 |
| 2025-09-30 | $3.14M 10-Q · filed 2025-11-18 | $9.29M derived: sum of 2 quarters · filed 2025-11-18 | $14.90M 10-Q · filed 2025-11-18 | $20.48M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $6.15M 10-Q · filed 2025-08-14 | $11.76M 10-Q · filed 2025-08-14 | $17.34M derived: sum of 3 quarters · filed 2026-05-20 | $21.58M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $5.61M 10-Q · filed 2026-05-20 | $11.19M derived: sum of 2 quarters · filed 2026-05-20 | $15.43M derived: sum of 3 quarters · filed 2026-05-20 | $21.43M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.82M derived: sum of 2 quarters · filed 2026-03-31 | $15.82M derived: sum of 3 quarters · filed 2026-03-31 | $27.37M 10-K · filed 2026-03-31 |
| 2024-09-30 | $4.24M 10-Q · filed 2025-11-18 | $10.24M derived: sum of 2 quarters · filed 2025-11-18 | $21.79M 10-Q · filed 2025-11-18 | $29.53M derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | $6.00M 10-Q · filed 2025-08-14 | $17.55M 10-Q · filed 2025-08-14 | $25.29M derived: sum of 3 quarters · filed 2025-08-14 | $33.41M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $11.55M 10-Q · filed 2025-05-15 | $19.30M derived: sum of 2 quarters · filed 2025-05-15 | $27.41M derived: sum of 3 quarters · filed 2025-05-15 | $31.68M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $15.86M derived: sum of 2 quarters · filed 2025-03-31 | $20.13M derived: sum of 3 quarters · filed 2025-03-31 | $25.95M 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.11M 10-Q · filed 2024-11-18 | $12.38M derived: sum of 2 quarters · filed 2024-11-18 | $18.20M 10-Q · filed 2024-11-18 | $26.42M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-06-30 | $4.27M 10-Q · filed 2024-08-19 | $10.09M 10-Q · filed 2024-08-19 | $18.31M derived: sum of 3 quarters · filed 2024-08-19 | $23.79M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $5.82M 10-Q · filed 2024-05-20 | $14.04M derived: sum of 2 quarters · filed 2024-05-20 | $19.52M derived: sum of 3 quarters · filed 2024-05-20 | $25.33M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $8.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $13.70M derived: sum of 2 quarters · filed 2024-04-16 | $19.51M derived: sum of 3 quarters · filed 2024-04-16 | $25.65M 10-K · filed 2024-04-16 |
| 2022-09-30 | $5.48M 10-Q · filed 2023-11-14 | $11.29M derived: sum of 2 quarters · filed 2023-11-14 | $17.43M 10-Q · filed 2023-11-14 | $41.45M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $5.81M 10-Q · filed 2023-08-14 | $11.95M 10-Q · filed 2023-08-14 | $35.97M derived: sum of 3 quarters · filed 2023-08-14 | $42.04M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $6.14M 10-Q · filed 2023-05-15 | $30.16M derived: sum of 2 quarters · filed 2023-05-15 | $36.23M derived: sum of 3 quarters · filed 2023-05-15 | $42.01M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $24.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $30.09M derived: sum of 2 quarters · filed 2023-04-17 | $35.87M derived: sum of 3 quarters · filed 2023-04-17 | $41.96M 10-K · filed 2023-04-17 |
| 2021-09-30 | $6.07M 10-Q · filed 2021-11-15 | $11.85M derived: sum of 2 quarters · filed 2021-11-15 | $17.94M 10-Q · filed 2021-11-15 | $22.61M derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-06-30 | $5.78M 10-Q · filed 2021-08-12 | $11.87M 10-Q · filed 2021-08-12 | $16.54M derived: sum of 3 quarters · filed 2021-08-12 | $19.28M derived: sum of 4 quarters · filed 2021-11-15 |
| 2021-03-31 | $6.09M 10-Q · filed 2021-05-12 | $10.77M derived: sum of 2 quarters · filed 2021-05-12 | $13.51M derived: sum of 3 quarters · filed 2021-11-15 | $13.91M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $7.42M derived: sum of 2 quarters · filed 2021-11-15 | $7.82M derived: sum of 3 quarters · filed 2021-11-15 | $8.87M 10-K · filed 2021-03-25 |
| 2020-09-30 | $2.74M 10-Q · filed 2021-11-15 | $3.14M derived: sum of 2 quarters · filed 2021-11-15 | $4.20M 10-Q · filed 2021-11-15 | $5.19M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $398.48K 10-Q · filed 2021-08-12 | $1.46M 10-Q · filed 2021-08-12 | $2.45M derived: sum of 3 quarters · filed 2021-08-12 | $3.53M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $1.06M 10-Q · filed 2021-05-12 | $2.05M derived: sum of 2 quarters · filed 2021-05-12 | $3.13M derived: sum of 3 quarters · filed 2021-05-12 | $5.68M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $990.63K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $2.07M derived: sum of 2 quarters · filed 2021-03-25 | $4.63M derived: sum of 3 quarters · filed 2021-03-25 | $5.87M 10-K · filed 2021-03-25 |
| 2019-09-30 | $1.08M 10-Q · filed 2020-11-13 | $3.64M derived: sum of 2 quarters · filed 2020-11-13 | $4.88M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $2.56M 10-Q · filed 2020-08-13 | $3.80M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |